Literature DB >> 9878040

The role of bacterial lipopolysaccharide-bound neutrophils in the pathogenesis of Kawasaki disease.

S Takeshita1, K Nakatani, H Kawase, S Seki, M Yamamoto, I Sekine, S Yoshioka.   

Abstract

To investigate the possible role of lipopolysaccharide (LPS, endotoxin) in the pathogenesis of Kawasaki disease, neutrophils from 15 patients with the disease and 7 with sepsis (4 infected with gram-negative bacteria and 3 with gram-positive bacteria) were analyzed by flow cytometry using anti-LPS and anti-CD14 monoclonal antibodies. The number of LPS- and CD14-positive neutrophils was dramatically higher early after the onset of Kawasaki disease and gram-negative sepsis but not with gram-positive sepsis. An immunoprecipitation analysis revealed LPS was bound to CD14 in vivo on neutrophils from Kawasaki disease patients. The mean plasma level of neutrophil elastase was significantly higher in the acute phase of Kawasaki disease than in the acute phase of sepsis. These findings suggest that exposure to LPS occurs at the onset of Kawasaki disease when LPS-bound neutrophils secrete excess protease (implicated in neutrophil-mediated endothelial injury) into the circulation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9878040     DOI: 10.1086/314600

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  20 in total

1.  Increased levels of circulating soluble CD14 in Kawasaki disease.

Authors:  S Takeshita; K Nakatani; H Tsujimoto; Y Kawamura; H Kawase; I Sekine
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

2.  Increased levels of lipopolysaccharide binding protein in plasma in children with kawasaki disease.

Authors:  Seiichiro Takeshita; Hiroshi Tsujimoto; Hiroko Kawase; Youichi Kawamura; Isao Sekine
Journal:  Clin Diagn Lab Immunol       Date:  2002-01

3.  Cytokine modulation with immune gamma-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment.

Authors:  M Gupta; G J Noel; M Schaefer; D Friedman; J Bussel; R Johann-Liang
Journal:  J Clin Immunol       Date:  2001-05       Impact factor: 8.317

4.  Sustained activation of neutrophils in the course of Kawasaki disease: an association with matrix metalloproteinases.

Authors:  M H Biezeveld; G van Mierlo; R Lutter; I M Kuipers; T Dekker; C E Hack; J W Newburger; T W Kuijpers
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

5.  Regulation of the expression of Fc gamma receptor on circulating neutrophils and monocytes in Kawasaki disease.

Authors:  K Nakatani; S Takeshita; H Tsujimoto; Y Kawamura; H Kawase; I Sekine
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

6.  Elevated serum levels of matrix metalloproteinase-9 (MMP-9) in Kawasaki disease.

Authors:  S Takeshita; T Tokutomi; H Kawase; K Nakatani; H Tsujimoto; Y Kawamura; I Sekine
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

7.  Expression of CD180, a toll-like receptor homologue, is up-regulated in children with Kawasaki disease.

Authors:  Miyoko Imayoshi; Shuichi Yamamoto; Mamie Watanabe; Shinji Nishimura; Katsuya Tashiro; Masafumi Zaitsu; Hakaru Tasaki; Masao Kimoto; Yuhei Hamasaki; Eiichi Ishii
Journal:  J Mol Med (Berl)       Date:  2005-12-31       Impact factor: 4.599

8.  Delayed apoptosis of circulating neutrophils in Kawasaki disease.

Authors:  H Tsujimoto; S Takeshita; K Nakatani; Y Kawamura; T Tokutomi; I Sekine
Journal:  Clin Exp Immunol       Date:  2001-11       Impact factor: 4.330

9.  Ulinastatin therapy in kawasaki disease.

Authors:  Satoru Iwashima; Masashi Seguchi; Tadashi Matubayashi; Takehiko Ohzeki
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

10.  Increased α1-antitrypsin levels in acute-phase Kawasaki disease as shown by SELDI-TOF MS analysis.

Authors:  Takahiro Kanai; Hirohiko Shiraishi; Ritei Uehara; Takane Ito; Mariko Y Momoi
Journal:  Pediatr Cardiol       Date:  2012-05-12       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.